Other languages Johnson & Johnson Swiss Exchange

Equities

JNJ

US4781601046

Market Closed - Swiss Exchange Other stock markets 09:06:28 25/05/2023 pm IST			After market 11:00:18 pm
136 ^USD	-0.73%		146.5	+7.72%

08/06	Top law firms in US opioid lawsuits to get hundreds of millions in fees	RE
07/06	J&J-backed Rapport Therapeutics shares debut nearly 6% higher	RE

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Top law firms in US opioid lawsuits to get hundreds of millions in fees	08/06
J&J-backed Rapport Therapeutics shares debut nearly 6% higher	07/06
J&J : la FDA approuve VELYS dans l'arthroplastie du genou	07/06
AbbVie's tight grip on Humira market raises concerns about biosimilars	07/06
J&J-backed Rapport Therapeutics raises $136 mln in US IPO	07/06
Borsa di Italia: Verso l'infinito e oltre	06/06
Bolsa de Madrid: Hasta el infinito y más allá	06/06
J&J : sollicite la FDA une indiation élargie du Prezcobix	05/06
J&J : essai concluant pour Carvykti dans le myélome multiple	04/06
J&J : essai prometteur pour Tecvayli dans le myélome multiple	04/06
Johnson & Johnson Ordered to Pay $260 Million In Talc Powder Case	04/06
Borsa di Italia: Mai contenti!	04/06
J&J must pay $260 million in latest talc trial, Oregon jury says	04/06
Legend Biotech Says Phase 2 Trial of Carvykti to Treat Multiple Myeloma Showed 'Deep, Durable' Responses	04/06
Johnson & Johnson Announces Results from a Subgroup Analysis of the Phase 3 CARTITUDE-4 Study	04/06
Johnson & Johnson Announces Data from the Phase 3 PERSEUS Study	04/06
Johnson & Johnson Announces New Data from the Phase 2 PALOMA-2 Study Evaluating Subcutaneous (SC) Amivantamab Combined with Lazertinib as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer	04/06
Johnson & Johnson Announces Longer-Term Data from the Pivotal Phase 1/2 Majestec-1 Study of TECVAYLI	03/06
J&J-backed Rapport Therapeutics seeks about $637 mln valuation in US IPO	03/06
J&J-backed Rapport Therapeutics seeks to raise $144 mln in US IPO	03/06

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 11:00 pm IST